摘要继发性甲状旁腺功能亢进症（SHPT）是维持性血液透析患者的常见并发症，约60%的慢性肾脏病患者存在不同程度的SHPT，这些患者的全段甲状旁腺激素控制率仅为55%左右。SHPT的临床表现主要包括全段甲状旁腺激素升高及持续性的钙磷代谢紊乱，可引起皮肤、骨骼及心脑血管等多系统疾病，严重影响患者的生存质量，甚至引起病死率的升高。该文根据相关研究，对SHPT的治疗进展进行综述。

abstractsSecondary hyperparathyroidism is a common complication among patients undergoing maintenance hemodialysis. Approximately 60% of patients with chronic kidney disease exhibit varying degrees of secondary hyperparathyroidism. The control rate of intact parathyroid hormone in these patients remains at approximately 55%. The clinical manifestations of secondary hyperparathyroidism primarily consist of elevated parathyroid hormone levels and persistent calcium and phosphorus metabolism disorders, which can lead to skin, bone, and cardiovascular and cerebrovascular diseases. These conditions significantly affect patients' quality of life and may even lead to increased mortality rates. This article aims to review the progress in the treatment of secondary hyperparathyroidism based on the latest relevant research.